-
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
PPMD is excited to learn that Capricor Therapeutics has completed the submission of its rolling […]
-
Capricor completes BLA submission to the FDA for the approval of its investigational cell therapy for Duchenne cardiomyopathy
Capricor Therapeutics, which received early funding from CureDuchenne, has completed a Biologics License Application (BLA) […]
-
My husband and I make a great team as we care for our sons
Occasionally I struggle to find a topic to write about in my weekly column. I […]
-
Top 10 MD news stories of 2024
During 2024, Muscular Dystrohy News Today covered the latest scientific studies, advances in treatment, and […]
-
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical […]
